角膜溃疡患者治疗中采用重组人表皮生长因子滴眼液治疗的效果观察  

The effect observation of recombinant human epidermal growth factor eye drops in the treatment of corneal ulcer patients

作　　者：冯淑杰[1] 

机构地区：[1]安阳市第五人民医院,河南安阳455004

出　　处：《临床研究》2017年第6期81-82,共2页Clinical Research

摘　　要：目的 探讨在角膜溃疡患者临床治疗中使用重组人表皮生长因子滴眼液的效果.方法 随机选取我院于2013年4月至2015年10月收治的78例角膜溃疡患者,分为两组,在常规处理基础上,对照组患者使用左氧氟沙星滴眼液,观察组患者使用重组人表皮生长因子滴眼液,对比分析两组临床治疗效果.结果 观察组治疗总有效率为97.14%,显著高于对照组的88.57%（P＜0.05）;在症状消失时间、住院时间比较上,观察组均短于对照组（P＜0.05）;两组均无患者出现严重不良反应.结论 将重组人表皮生长因子滴眼液应用于角膜溃疡临床治疗中,可促进治疗效果显著提高,且表现出较高的安全性,使患者更快康复.Objective To investigate the effect of recombinant human epidermal growth factor eye drops in the clinical treatment of patients with corneal ulcer. Methods From April 2013 to October 2015 period, 78 cases of patients with corneal ulcer in our hospital were randomly selected, and were divided into 2 groups On the basis of routine treatment, patients in the control group were treated with the left ofloxacin eye drops, the observation group was treated with recombinant human epidermal growth factor eye drops, the clinical treatment effects of the two groups were compared and analyzed. Results The total effective rate of observation group was 97.14%, which was significantly higher than 88.57% of the control group （P〈 0.05）; the disappearance time of symptoms and hospitalization time of the observation group were significantly shorter than those of the control group （P〈0.05）; no patients experienced serious adverse reactions in both two groups. Conclusion Re- combinant human epidermal growth factor eye drops in the clinical treatment of patients with corneal ulcer can significantly improve the treatment effect with high safety, and can prornoto faster recovery of patients.

关 键 词：角膜溃疡 重组人表皮生长因子滴眼液 

分 类 号：R772.21[医药卫生—眼科]